Polycomponent Vaccine for Aerosol Application
Aerosol Application of Polycomponent Vaccine VP-4 for Treatment and Prophylaxis of Pyo-Inflammatory and Infectious-and-Allergic Diseases
Tech Area / Field
8 Project completed
Senior Project Manager
Weaver L M
Research Center of Toxicology and Hygienic Regulation of Biopreparations, Russia, Moscow reg., Serpukhov
- Greencross Vaccine Corporation, Korea, Kyonggido\nFraunhofer USA - Center for Molecular Biotechnology, USA, DE, Newark
Project summaryObjective of the project: substantiation and development of the method for aerosol application of polycomponent vaccine VP-4 obtained from antigen of Stapylococcus, Proteus, Klebsiella pneumoniae and Escherichia coli for treatment and prophylaxis of pyo-inflammatory and infectious-and-allergic diseases.
TECHNICAL APPROACH AND METHODOLOGY
Respiratory organs’ diseases are considered to be the most spread ones nowadays.
Anthropogenic load can be envisioned as a great threat for population, being one of risk factors for arising and long taking chronic diseases of respiratory organs. It takes place bacterial and viral infections, making a part of inflammatory process.
Last years, immunotherapy and prophylaxis of these diseases much consideration are being given to immunomodulators, particularly ones based on antigenic complexes isolated from microbial cells.
For treatment and prophylaxis of pyo-inflammatory and infectious-and-allergic diseases of respiratory organs at Moscow Research Institute for Vaccines and Serums named after I.I.Mechnikov (MRIVS) it has been developed original therapeutic cell-free polycomponent vaccine VP-4 based on antigenic complexes isolated from S.aureus, K.pneumoniae, E.coli, P.vulgaris VP-4 serves as active stimulator of antigenspecific and nonspecific organism reactivity (patent No 2083223 of 27.05.94). Vaccine VP-4 causes producing antibodies to Staphylococcus, K.pneumoniae, Proteus and E.coli, and also increases an organism resistance to above-mentioned microbes and stimulates nonspecific resistance to a number of other conventionally-pathogenic bacteria. Protective activity of vaccine as well as stimulation of immunity have been studied under different vaccination ways – subcutaneous, oral and intranasal-and oral. The preparation was tested on a considerable number of patients and allowed to be applied in clinical practice (Order of Ministry of Health of Russian Federation of 17.11.93).
Recently, in the world practice of vaccinotherapy developed the methods of non-injection particularly aerosol, vaccine application as evidenced by set up a specialized laboratory at “Battelle Corporation” (USA) in 1998. Aerosol vaccination, in opinion of some researchers, offers major advantages over the other methods. One of them is rapid lowering cases of hepatitis or AIDS under vaccination. Converted into aerosol state, the vaccine goes to respiratory organs, absorbing through mucous membranes, and causes early reaction of an organism, where infection agent forms colonies and pathological focus is developed. Key factors determining the effectiveness of aerosol immunization is the application of perfect methods of generation of vaccine aerosol and control over its characteristics, such as aerosol size particles and their distribution over respiratory tract, reliable estimation of in fact inhaled vaccine aerosol doses and its application place.
To apply polycomponent vaccine VP-4 by aerosol method, it is necessary to refine methodology of group and inpidual immunization, taking advantages of technical facilities allowed to maintain specific vaccine properties under aerosolization, to perfect obtaining optimum size particle distribution (SPD) and inhaled doses of vaccine aerosol by values of humoral and cell immunity, allergenic activity and toxicity. The effectiveness of aerosol vaccination must checked upon model infectious.
It will be developed the method of aerosol application of polycomponent vaccine VP-4 for treatment and prophylaxis of pyo-inflammatory and infectious-and-allergenic diseases in respiratory organs, yielding a high therapeutic effectiveness and low reactogenicity.
FOREIGN COLLABORATORS would take part in the project under the following directions:
· information support of the project;
· preparation and publication of papers;
· scientific information exchange and extensive discussion seminars.
The International Science and Technology Center (ISTC) is an intergovernmental organization connecting scientists from Kazakhstan, Armenia, Tajikistan, Kyrgyzstan, and Georgia with their peers and research organizations in the EU, Japan, Republic of Korea, Norway and the United States.
ISTC facilitates international science projects and assists the global scientific and business community to source and engage with CIS and Georgian institutes that develop or possess an excellence of scientific know-how.